Recommendations on PCV20 vaccine in adults and at-risk populations
The efficacy, safety and cost-effectiveness of PCV20 support its use in preventing invasive and noninvasive pneumococcal disease across age groups, including those with underlying health conditions.
Authors
- Francesco Blasi (ORCID: https://orcid.org/0000-0002-2285-9970)
- Mariangela Valentina Puci (ORCID: https://orcid.org/0000-0001-5656-6845)
- Giovanni Sotgiu (ORCID: https://orcid.org/0000-0002-1600-4474)
- Michele Bartoletti (ORCID: https://orcid.org/0000-0002-1099-3283)
- Stefano Aliberti (ORCID: https://orcid.org/0000-0002-0090-4531)
- Paolo Bonanni (ORCID: https://orcid.org/0000-0003-2875-3744)
Institutions
- Humanitas University (IT)
- University of Sassari (IT)
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- IRCCS Humanitas Research Hospital (IT)
- University of Florence (IT)
Publication Details
- Journal
- European Respiratory Review
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1183/16000617.0016-2025
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00